Our understanding and treatment of postpartum psychiatric illnesses remain profoundly inadequate,” experts write.

Waiting for treatment to start can be an excruciating period for cancer patients. There can be fears that the disease is spreading, or progressing to a point where therapies becom ...

Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her on Mastodon and Bluesky. You can reach Helen on ...

Sarah covers how industries like food and tobacco affect Americans’ bodies and minds. Her interests include ultra-processed foods; smoke-free tobacco; and wellness trends like perimenopause products ...

Helen Branswell covers issues broadly related to infectious diseases, including outbreaks, preparedness, research, and vaccine development. Follow her on Mastodon and Bluesky. You can reach Helen on ...

Lev’s reporting has explored Americans’ deadly hostility to addiction medications, subpar treatment offered in jails and prisons, shifts in the illicit drug supply and consumption behavior, ...

Eli Lilly filed six lawsuits against U.S. companies it accuses of illegally selling black-market versions of its experimental obesity drug retatrutide ...

Adam Feuerstein is a senior writer and biotech columnist, reporting on the crossroads of drug development, business, Wall Street, and biotechnology. He is also a co-host of the weekly biotech podcast ...

Not long after guidelines shifted to considering statin therapy as early as age 30, new research from France suggests there may be no harm in stopping the cholesterol-lowering drugs at age 75 in ...

It's no mystery. History tells us that President Trump’s executive order calling for the MMR to be split into separate shots could do real harm.

Jason is a general assignment reporter, with particular focus on genetic medicine and rare disease. Confidential tips can be sent on Signal at JasonMast.77. Definium Therapeutics said Wednesday that ...

Ed’s stories explore prescription drug pricing, affordability and access, as well issues surrounding patents, litigation, and legislation. He is also the author of the morning Pharmalittle newsletter ...